SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
5/9/2022
Diamyd Medical's principal owner transfers half of his holdings in Diamyd Medical to his children
4/29/2022
Diamyd
®
meta-analysis is now available as Open Access publication
4/20/2022
New meta-analysis with Diamyd
®
published in scientific journal
4/13/2022
New clinical trial will evaluate an additional injection (booster) with Diamyd
®
3/30/2022
Quarterly Report II 21/22
3/28/2022
Diabetes prevention project coordinated by Diamyd Medical to be presented at scientific conference
3/15/2022
Diamyd Medical has opened the first clinic for the recruitment of patients for a Phase III trial in Type 1 Diabetes
2/8/2022
Clinical trial in type 1 diabetes with Diamyd Medical's Remygen
®
is fully recruited
2/6/2022
Diamyd Medical proceeds with initiation of Type 1 Diabetes Phase III trial in Europe
1/26/2022
Quarterly Report I 21/22
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research